BioTuesdays

Category - Markets

NeoGenomics
Markets

Leerink starts Neogenomics at OP; PT $18

Leerink initiated coverage of Neogenomics (NASDAQ:NEO) with an “outperform” rating and price target of $18. The stock closed at $12.84 on August 20. Analyst Puneet Souda writes that Neogenomics is a “uniquely positioned...

August 21, 2018
Lannett Co. Logo
Markets

Roth cuts Lannett Co. to neutral; PT to $8 from $23

Roth Capital Partners downgraded Lannett Co. (NYSE AMER:LCI) to “neutral” and slashed its price target to $8 from $23 after the company lost an important customer and issued a profit warning. Near midday on August 20...

August 20, 2018
Liquidia Logo
Markets

Needham starts Liquidia Technologies at buy; PT $30

Needham initiated coverage of Liquidia Technologies (NASDAQ:LQDA) with a “buy” rating and $30 price target. The stock closed at $14.90 on August 17. Liquidia is developing LIQ861, a differentiated inhaled treatment for...

August 20, 2018
Achieve Life Sciences Logo
Markets

Ladenburg starts Achieve Life Sciences at buy; PT $12

Ladenburg Thalmann initiated coverage of Achieve Life Sciences (NASDAQ:ACHV) with a “buy” rating and $12 price target. The stock finished at $2.80 on August 17. Achieve is developing cytisine, a natural compound with...

August 20, 2018
AcelRx Pharma Logo
Markets

Ladenburg starts AcelRx Pharma at buy; PT $7

Ladenburg Thalmann launched coverage of AcelRx Pharmaceuticals (NASDAQ:ACRX) with a “buy” rating and price target of $7. The stock closed at $2.95 on August 15. AcelRx is focused on the development of acute pain...

August 16, 2018
Cytori Logo
Markets

Maxim cuts Cytori Therapeutics to hold, removes PT

Maxim Group downgraded Cytori Therapeutics (NASDAQ:CYTX) to “hold” from “buy” and removed its price target, citing capital concerns. The stock closed at 40 cents on August 14. “Our fundamental view around the...

August 15, 2018
ObsEva Logo
Markets

Leerink resumes coverage of ObsEva at OP; PT $25

Leerink resumed coverage of ObsEva SA (NASDAQ:OBSV) with an “outperform” rating and $25 price target. The stock finished at $13 on August 14. “We believe that at current levels the stock does not fully reflect the...

August 15, 2018
Dicerna Logo
Markets

HCW ups Dicerna Pharma to buy; PT $21

H.C. Wainwright upgraded Dicerna Pharmaceuticals (NASDAQ:DRNA) to “buy” from “neutral” and raised its price target to $21 from $14, citing broad progress across the company’s pipeline. The stock closed at $14.82 on...

August 15, 2018
Idera Pharma Logo
Markets

JP Morgan ups Idera Pharma to OW; PT $15

JP Morgan upgraded Idera Pharmaceuticals (NASDAQ:IDRA) to “overweight” with a December 2019 price target of $15, following a period of restriction and a “not-rated” designation. JP Morgan had rated the stock, which...

August 15, 2018